NextPlat Cuts Q3 Loss 66% as 340B Contracts Lift Margins to 35%
Image
Hallandale Beach, Fla. – November 12, 2026 -- NextPlat Corp (NASDAQ: NXPL) cut its third-quarter net loss attributable to common stockholders by about 66% to roughly $0.7 million, or $0.28 per diluted share, as higher-margin 340B pharmacy contracts replaced lower-margin retail prescription sales. The prior-year loss was about $2.2 million, or $0.84 per share.
Consolidated revenue for the quarter ended Sept. 30 fell to about $10.5 million from $13.8 million a year earlier. The company attributed the drop to lower reimbursement rates and lower retail prescription volumes in its healthcare operations. Overall gross margin rose to about 35.0% from 19.9%.